articleJNCI Journal of the National Cancer InstituteApr 15, 2003BRONZE OA

BRAF Mutation in Papillary Thyroid Carcinoma

Johns Hopkins University · Ben-Gurion University of the Negev

PubMed
Indexed incrossrefpubmed

Abstract

The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)-->adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an…

Citation impact

922
total citations
FWCI
23.36
Percentile
100%
References
12
Citations per year

Authors

10

Topics & keywords

Keywords
  • Medicine
  • Transversion
  • Thyroid carcinoma
  • Missense mutation
  • Thyroid
  • Cancer research
  • Mutation
  • Carcinoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding